Combined pharmacologic therapy in a rabbit model of proliferative vitreoretinopathy (PVR)
- PMID: 10657752
- DOI: 10.1159/000055583
Combined pharmacologic therapy in a rabbit model of proliferative vitreoretinopathy (PVR)
Abstract
Purpose: This study was designed to evaluate the efficacy of a combined treatment, previously used to prevent fibrosis after glaucoma surgery, to inhibit an experimental model of proliferative vitreoretinopathy (PVR).
Methods: Two groups of albino rabbits were used. In the control group (group 1, n = 14), experimental PVR was induced using vitrectomy, retinotomies, cryotherapy and intraocular injection of platelet-rich plasma. In the experimental group (group 2, n = 15), after PVR was induced, the following treatment was administered for 4 weeks: systemic methylprednisolone, sodium diclofenac and colchicine combined with topical atropine 1%, adrenaline 10% and dexamethasone phosphate 0.1%. Follow- up consisted of fundus examination for 4 weeks. Results were classified according to Fastenberg's classification. Only retinal detachments were considered to compare the two groups. Nonparametric test was used.
Results: Retinal detachments were observed in 85.7% of group 1 and 33.3% of group 2 at the end of the follow-up (p<0.01). No major systemic complications were observed.
Conclusions: Combined therapy seems to be useful for treating experimental PVR.
Copyright 2000 S. Karger AG, Basel.
Similar articles
-
Use of perfluorocarbon liquids, silicone oil, and 5-fluorouracil in the management of experimental PVR.Int Ophthalmol. 1998-1999;22(4):239-46. doi: 10.1023/a:1006336831730. Int Ophthalmol. 1998. PMID: 10674869
-
The role of retinotomy in an experimental rabbit model of proliferative vitreoretinopathy.Curr Eye Res. 1997 May;16(5):422-7. doi: 10.1076/ceyr.16.5.422.7052. Curr Eye Res. 1997. PMID: 9154379
-
Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2318-25. Invest Ophthalmol Vis Sci. 1996. PMID: 8843916
-
[Proliferative vitreoretinopathy: prophylactic treatment].J Fr Ophtalmol. 2014 Nov;37(9):737-43. doi: 10.1016/j.jfo.2014.04.003. Epub 2014 Jul 8. J Fr Ophtalmol. 2014. PMID: 25012973 Review. French.
-
[Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy].J Fr Ophtalmol. 2004 Nov;27(9 Pt 1):1051-9. doi: 10.1016/s0181-5512(04)96264-x. J Fr Ophtalmol. 2004. PMID: 15557870 Review. French.
Cited by
-
Experimental Models to Study Epithelial-Mesenchymal Transition in Proliferative Vitreoretinopathy.Int J Mol Sci. 2023 Feb 24;24(5):4509. doi: 10.3390/ijms24054509. Int J Mol Sci. 2023. PMID: 36901938 Free PMC article. Review.
-
Proliferative Vitreoretinopathy: A Reappraisal.J Clin Med. 2023 Aug 14;12(16):5287. doi: 10.3390/jcm12165287. J Clin Med. 2023. PMID: 37629329 Free PMC article. Review.
-
Proliferative Vitreoretinopathy: A Review.Int Ophthalmol Clin. 2019 Winter;59(1):221-240. doi: 10.1097/IIO.0000000000000258. Int Ophthalmol Clin. 2019. PMID: 30585928 Free PMC article. Review.
-
The effect of a preoperative subconjuntival injection of dexamethasone on blood-retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial.Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):957-62. doi: 10.1007/s00417-010-1319-8. Epub 2010 Feb 25. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 20182883 Free PMC article. Clinical Trial.
-
Proliferative Vitreoretinopathy in Retinal Detachment: Perspectives on Building a Digital Twin Model Using Nintedanib.Int J Mol Sci. 2024 Oct 15;25(20):11074. doi: 10.3390/ijms252011074. Int J Mol Sci. 2024. PMID: 39456855 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials